Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2545 | Medical Record Review Wiki | 0.32 |
| drug4444 | Toraymyxin PMX-20R (PMX Cartridge) Wiki | 0.32 |
| drug4688 | VitalTalk communication skills training Wiki | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug247 | Aerosol-reducing Mask Wiki | 0.32 |
| drug97 | ACP Decisions Video Program Wiki | 0.32 |
| drug3600 | Recombinant human alkaline phosphatase Wiki | 0.32 |
| drug3301 | Plasma expansion with Ringer's Acetate Wiki | 0.32 |
| drug116 | ALLOCETRA-OTS Wiki | 0.32 |
| drug4079 | Standard Mask Wiki | 0.32 |
| drug2184 | Intervention training: Wiki | 0.32 |
| drug2286 | LEAF-4L6715 Wiki | 0.32 |
| drug5055 | microcirculation recording Wiki | 0.32 |
| drug2466 | MMR vaccine Wiki | 0.32 |
| drug3155 | Phage Therapy Wiki | 0.32 |
| drug59 | 300 mg of omega3-FA Wiki | 0.22 |
| drug866 | CT-Scan Wiki | 0.22 |
| drug4857 | blood donation SMS Wiki | 0.18 |
| drug4698 | Vitamin Super B-Complex Wiki | 0.18 |
| drug2804 | Nitazoxanide Wiki | 0.08 |
| drug3195 | Placebo Wiki | 0.05 |
| drug453 | Azithromycin Wiki | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014115 | Toxemia NIH | 0.72 |
| D011552 | Pseudomonas Infections NIH | 0.32 |
| D011645 | Puerperal Infection NIH | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D063130 | Maternal Death NIH | 0.32 |
| D000071074 | Neonatal Sepsis NIH | 0.32 |
| D019446 | Endotoxemia NIH | 0.32 |
| D066087 | Perinatal Death NIH | 0.32 |
| D011251 | Pregnancy Complications, Infectious NIH | 0.18 |
| D012772 | Shock, Septic NIH | 0.18 |
| D016470 | Bacteremia NIH | 0.18 |
| D018746 | Systemic Inflammatory Response Syndrome NIH | 0.16 |
| D003643 | Death, NIH | 0.16 |
| D012769 | Shock, NIH | 0.12 |
| D058186 | Acute Kidney Injury NIH | 0.12 |
| D011014 | Pneumonia NIH | 0.05 |
| D011024 | Pneumonia, Viral NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D013577 | Syndrome NIH | 0.03 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.03 |
| D055371 | Acute Lung Injury NIH | 0.03 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.02 |
| D003141 | Communicable Diseases NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100806 | Sepsis HPO | 1.00 |
| HP:0003811 | Neonatal death HPO | 0.32 |
| HP:0040187 | Neonatal sepsis HPO | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001919 | Acute kidney injury HPO | 0.12 |
| HP:0002090 | Pneumonia HPO | 0.05 |
Navigate: Correlations HPO
There are 10 clinical trials
A study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to COVID-19 or other agents.
Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST), compared to baseline measurement
Measure: Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus Time: When achieved according to protocol, approximately 3-10 minutes after interventionDescription: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) during baseline measurement.
Measure: Descriptive renal oxygenation and blood flow in critical illness due to sepsis Time: During Critical illness - at one time pointDescription: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) images stratified in groups in regards to KDIGO grade during exam.
Measure: Descriptive renal oxygenation and blood flow in critical illness in no/low grade AKI or high grade AKI. Time: During Critical illness - at one time pointMaternal and neonatal infections are among the most frequent causes of maternal and neonatal deaths, and current antibiotic strategies have not been effective in preventing many of these deaths. Recently, a randomized clinical trial conducted in a single site in The Gambia showed that treatment with oral dose of 2 g azithromycin vs. placebo for all women in labor reduced selected maternal and neonatal infections. However, it is unknown if this therapy reduces maternal and neonatal sepsis and mortality. The A-PLUS trial includes two primary hypotheses, a maternal hypothesis and a neonatal hypothesis. First, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce maternal death or sepsis. Second, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce intrapartum/neonatal death or sepsis.
Description: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.
Measure: Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group. Time: within 6 weeks (42 days)Description: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group
Measure: Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group Time: 4 weeks (28 days) post-deliveryDescription: Fever (>100.4°F/38°C) in addition to one or more of the following: fetal tachycardia ≥160 bpm, maternal tachycardia >100 bpm, tender uterus between contractions, or purulent/foul smelling discharge from uterus prior to delivery.
Measure: Incidence of chorioamnionitis Time: prior to deliveryDescription: Fever (>100.4°F/38°C) in addition to one or more of maternal tachycardia >100 bpm, tender uterine fundus, or purulent/foul smelling discharge from uterus after delivery.
Measure: Incidence of endometritis Time: within 42 days post-deliveryDescription: Wound infection (Purulent infection of a perineal or Cesarean wound with or without fever. In the absence of purulence, requires presence of fever >100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration); Abdominopelvic abscess (Evidence of pus in the abdomen or pelvis noted during open surgery, interventional aspiration or imaging); Pneumonia (Fever >100.4°F/38°C and clinical symptoms suggestive of lung infection including cough and/or tachypnea >24 breaths/min or radiological confirmation); Pyelonephritis (Fever >100.4°F/38°C and one or more of the following: urinalysis/dip suggestive of infection, costovertebral angle tenderness, or confirmatory urine culture); Mastitis/breast abscess or infection (Fever >100.4°F/38°C and one or more of the following: breast pain, swelling, warmth, redness, or purulent drainage).
Measure: Incidence of other infections Time: within 42 days post-deliveryDescription: Use of subsequent maternal antibiotic therapy after randomization to 42 days postpartum for any reason.
Measure: Incidence of use of subsequent maternal antibiotic therapy Time: after randomization to 42 days post-deliveryDescription: Time from drug administration until initial discharge after delivery (time may vary by site).
Measure: Maternal initial hospital length of stay Time: within 42 days post-deliveryDescription: Maternal readmissions within 42 days of delivery
Measure: Incidence of maternal readmissions Time: within 42 days post-deliveryDescription: Maternal admission to special care units
Measure: Incidence of maternal admission to special care units Time: within 42 days post-deliveryDescription: Maternal unscheduled visit for care
Measure: Incidence of maternal unscheduled visit for care Time: within 42 days post-deliveryDescription: Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effects.
Measure: Incidence of maternal GI symptoms Time: within 42 days post-deliveryDescription: Maternal death due to sepsis using the Global Network algorithm for cause of death
Measure: Incidence of maternal death due to sepsis Time: within 42 days post-deliveryDescription: Incidence of other neonatal infections.
Measure: Incidence of other neonatal infections (e.g. eye infection, skin infection) Time: within 42 days post-deliveryDescription: Neonatal initial hospital length of stay, defined as time of delivery until initial discharge (time may vary by site).
Measure: Neonatal initial hospital length of stay Time: within 28 days of deliveryDescription: Neonatal readmissions within 42 days of delivery
Measure: Incidence of neonatal readmissions Time: within 42 days of deliveryDescription: Neonatal admission to special care units
Measure: Incidence of neonatal admission to special care units Time: within 28 days of deliveryDescription: Neonatal unscheduled visit for care
Measure: Incidence of neonatal unscheduled visit for care Time: within 42 days post-deliveryDescription: Neonatal death due to sepsis using the Global Network algorithm for causes of death
Measure: Incidence of neonatal death due to sepsis Time: within 28 days of deliveryDescription: Pyloric stenosis within 42 days of delivery, defined as clinical suspicion based on severe vomiting leading to death, surgical intervention (pyloromyotomy) as verified from medical records, or radiological confirmation.
Measure: Incidence of pyloric stenosis within 42 days of delivery Time: within 42 days of deliveryProspective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases.
Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.
Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection. Time: Day of enrollment through Day 5This is an open label phase II study of treatment with LEAF-4L6715 in patients who experience severe acute respiratory distress syndrome (ARDS) and are receiving artificial respiratory support due to COVID-19, Sepsis or other Causes. The purpose of this study is to evaluate the improvement in PaO2/FiO2 by more than 25% in patients treated with LEAF-4L6715.
Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. The study has three distinct SA-AKI trial populations: 1. The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization. 2. A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and <45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization. 3. A COVID-19 population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients. There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.
Description: To demonstrate an effect of recAP on 28 day all cause mortality
Measure: 28-day all-cause mortality Time: 28 daysDescription: MAKE 90: dead or on RRT or ≥25% decline in estimated glomerular filtration rate (eGFR) on Day 90 relative to the known or assumed pre-AKI reference level.
Measure: To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE). Time: 90 DaysDescription: Days alive and free of organ support through Day 28, i.e., days alive with no MV, RRT, vasopressors or inotropes (with death within 28 days counting as zero days).
Measure: To investigate the effect of recAP on use of organ support, i.e., mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors or inotropes. Time: 28 daysDescription: Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).
Measure: To investigate the effect of recAP on length of stay (LOS) in ICU. Time: 28 daysDescription: Time to death through Day 90.
Measure: To investigate the effect of recAP on 90-day allcause mortality Time: 90 daysThe objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of myeloid-derived suppressor cells (MDSCs) Time: 14 days post-vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 30 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 60 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 12 months post vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 14 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 30 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 60 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 12 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 14 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 30 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 60 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 3 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 4 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 5 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 6 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 7 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 8 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 9 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 10 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 11 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 12 months post-vaccinationA phase II, multi-center (approximately 10 sites in Israel), randomized, placebo-controlled, dose- finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in up to 160 adult sepsis patients with organ sysfunction.
Description: Number and severity of AEs and SAEs throughout 28 days follow up period
Measure: To compare the safety of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients Time: 28 daysDescription: Change from baseline in SOFA score throughout 28 days
Measure: To compare the efficacy of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients Time: 28 daysDescription: Vasopressor-free days over 28 days.
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Ventilator-free days over 28 days
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients. Time: 28 daysDescription: Days without renal replacement therapy (dialysis).
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Time in ICU and time in hospital
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Number of days with creatinine ≤ Baseline levels +20%.
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: All-cause mortality at Day 28 following first dose
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Changes in CRP levels
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Number and severity of AEs and Serious Adverse Events (SAEs) throughout 12 months follow up period
Measure: Assess long term safety follow up Time: 12 monthsBacteriophage treatment in Covid-19 patients being treated with Anti-Microbials for Pneumonia or Bacteremia/Septicemia.
This prospective observational pilot study investigates circulatory coherence in patients with COVID and non-COVID sepsis by comparison of microcirculation, endothelial glycocalyx, and clinical course
Description: PPV describes microcirculation dysfunction
Measure: change in Proportion of Perfused Vessels (PPV) parameter Time: 1st, 2nd and 3rd dayDescription: Syndecan-1 is a marker of endothelial glycocalyx
Measure: change in Syndecan-1 serum concentration Time: 1st, 2nd and 3rd dayDescription: albuminuria is a marker of glomerular endothelial cells dysfunction
Measure: change in albuminuria Time: 1st, 2nd and 3rd dayDescription: mortality in 28 days from ICU admission
Measure: mortality in 28 days Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports